Kyverna Therapeutics (KYTX) Non-Current Assets (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Non-Current Assets data on file, last reported at $15.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 17.64% year-over-year to $15.3 million; the trailing twelve-month figure through Mar 2026 stood at $50.6 million (down 8.3% YoY), and the FY2025 full-year result was $10.9 million, down 22.58% from the prior year.
• Non-Current Assets for Q1 2026 stood at $15.3 million, up from $10.9 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $15.3 million in Q1 2026 and bottomed at $10.9 million in Q4 2025.
• The 4-year median for Non-Current Assets is $13.9 million (2024), against an average of $13.5 million.
• The widest annual swing landed in 2025, when Non-Current Assets fell 22.58%; it then gained 17.64% in 2026.
• A 4-year view of Non-Current Assets shows it stood at $14.5 million in 2023, then declined by 3.35% to $14.0 million in 2024, then decreased by 22.58% to $10.9 million in 2025, then surged by 40.7% to $15.3 million in 2026.
• The last three Non-Current Assets figures came in at $15.3 million (Q1 2026), $10.9 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.

Peer Comparison